ArticleJournal of the American Heart Association2026
Associations of Serum Complement Biomarkers With Adverse Clinical Outcomes Among Patients With Ischemic Stroke.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe complement system plays a crucial role in immune regulation and inflammatory response and is believed to be involved in the onset and progression of ischemic stroke. Therefore, we aimed to investigate the associations of baseline serum complement C3 and C4 levels with the prognosis of ischemic stroke.
methodsWe measured baseline serum complemental C3 and C4 levels in 3979 patients with ischemic stroke from the Minhang Stroke Cohort. The primary outcome was death or major disability at discharge after ischemic stroke. Secondary outcomes included major disability, death, and pneumonia. In addition, we constructed a complement biomarker score based on serum complement C3 and C4 levels to systematically evaluate the impact of the complement system on the prognosis among patients with ischemic stroke.
resultsAmong the 3979 patients with ischemic stroke, 1360 (34.18%) experienced death or major disability at discharge. After multivariable adjustment, the odds ratios of the primary outcome for the highest versus the lowest quartile were 1.34 (95% confidence intervals [CI], 1.06-1.69;
conclusionsHigh serum complement C3 and C4 levels were associated with increased risks of adverse outcomes at discharge after ischemic stroke, suggesting that the complement system might be implicated in the progression of ischemic stroke and could be potential intervention targets for improving prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.